Phase 2 N=129 Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
Acute Bacterial Conjunctivitis
Primary: Clinical Cure Rate — 37; 31; 27; 33 Participants — p=0.0137
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
Acute Infectious Conjunctivitis (Disorder)
Primary: Complete Clinical Resolution — 9; 0 Participants
Phase 4 N=162 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Bacterial Conjunctivitis
Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates
Phase 4 N=24 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
Bacterial Conjunctivitis
Primary: Exploratory Outcomes From Digital Photography — 17; 7 Participants
N/A N=28 Reducing Adenoviral Patient Infected Days
Conjunctivitis · Adenoviral Conjunctivitis
Primary: Percent Change From Peak Viral Load — 1.9; 13.2 Percent of peak Viral Load — p=0.02
Phase 2 N=269 Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9) — 37; 20 Participants
Phase 4 N=23 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale
Phase 3 N=1,161 A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis
Acute Bacterial Conjunctivitis
Primary: Clinical Resolution — 167; 147 Participants
Phase 2 N=154 A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. — 2.020; 2.398; 2.515 units on a scale
Phase 3 N=753 Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
Bacterial Conjunctivitis
Primary: Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 5 — 111; 0; 95 Participants — p=0.127
Phase 2 N=120 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1 — 2.573; 2.500; 1.217; 2.647 units on a scale
N/A N=128 A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis
Conjunctivitis
Primary: Sensitivity and Specificity of RPS Adeno Detector IV Compared to Cell Culture. — 90; 96 percentage of cases
N/A N=42 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Chlamydial Conjunctivitis
Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants
Phase 4 N=171 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7 — 78.6; 84.4 Percentage of Patients
Phase 2 N=90 AGN-229666 for the Treatment of Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching Score at Day 1 — 0.500; 0.319; 1.867 Score on a scale
N/A N=21 Effect of Olopatadine on Allergic Tear Mediators
Allergic Conjunctivitis
Primary: Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine…
Phase 3 N=87 Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching Score Compared to Placebo Period1 — 0.4; 1.7 score — p=<0.001
Phase 3 N=578 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 — 74.9; 65.2 Percentage of Patients
Phase 3 N=957 A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.
Acute Bacterial Conjunctivitis
Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis — 90; 63 Participants
Phase 3 N=345 Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.38; 0.47; 0.59; 1.91 units on a scale
Phase 3 N=140 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale — 4.4; -3.4 Scores on a Scale
Phase 3 N=859 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6 — 51.8; 41.3 Percentage of Patients
Phase 4 N=18 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Hypersensitivity
Primary: Symptoms — 15.3; 11.3; 13.3; 9.8 Units on a scale
Phase 2 N=150 Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
Bacterial Conjunctivitis
Primary: Change From Baseline Bacterial Culture — 30; 16; 26; 29 cultures — p=0.002
Phase 3 N=303 Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Number of Subjects With Clinical Resolution of Bacterial Conjunctivitis — 71; 59 Participants — p=0.2219
Phase 3 N=1,179 Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Clinical Cure at the Day 4 (EOT)/Exit Visit — 62.5; 50.6 percentage of subjects
Phase 3 N=130 A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change in Ocular Itching Score by Visit — -0.6; -0.9; -1.3; -1.7 score
Phase 3 N=101 Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (16 Hours Post-dose) — 1.91; 2.00; 1.65; 2.48 units on a scale
Phase 4 N=157 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject 3 Minutes Post Challenge on Day 0 — 0.40; 0.76; 2.00 Scores on a Scale
Phase 3 N=73 OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 1.68; 2.66 units on a scale